The life science industry is all hands on deck in the race to develop vaccines, therapies and diagnostics in the fight against coronavirus. But while some prosper, many in the sector are forced to halt clinical trials and mothball labs

Low profitability of antibiotics means fight against drug resistance relies on a handful of companies

Investment in later stage clinical development is needed to back up recent improvements in the discovery of new antibiotics, and to ensure the use of novel products is managed to maintain their effectiveness  

Armed with bear spray, microbiologist Naowarat ‘Ann’ Cheeptham is searching for hardy, less-studied bacteria that could play a role in stemming the antimicrobial resistance crisis

European Court of Auditors says it will investigate whether EU attempts to tackle antibiotic resistance provide value for money, on same day that health and food agencies say the problem is getting worse

Industry says regulators must intensify preparations for a worst-case scenario. ‘Time is almost up’, warns European Commission president

Time from patent to patient has increased by more than a year, Institute of Cancer Research finds in new study

Plants traits introduced by Crispr gene editing will be subject to the same lengthy regulatory process as 1980s-style genetically modified organisms containing genes from other species, Europe’s highest court rules

Vytenis Andriukaitis calls ‘fake news’ on Trump drug price blame game. Tariffs on medicines – if ever proposed by the US – would be ‘a humanitarian tragedy’, he says